IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
IDEAYA Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$33.81+0.96 (+2.92%)
Close on Oct 19, 2026
- Market cap
- $3.11B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$4.55 (+15.55%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
IDEAYA Biosciences, Inc. reported revenue of $234.13M for the twelve months to Jun 30, 2026. Free cash flow was -$113.87M.
Revenue
$234.13M
TTM Q2 2026
Operating income
-$216.95M
TTM Q2 2026
Free cash flow
-$113.87M
TTM Q2 2026
EPS, diluted
-$1.94
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.11B
- P/E ratio
- –
- Price to sales
- 13.29
- Price to book
- 2.60
- Dividend yield
- –
- Free cash flow yield
- -3.66%
Fundamentals
- Revenue
- $234.13M
- Net income
- -$175.02M
- EPS, diluted
- -$1.94
- Free cash flow
- -$113.87M
- Book value per share
- $13.02
- Diluted shares
- 92M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$234.13M
Operating income
-$216.95M
Net income
-$175.02M
EPS, diluted
-$1.94
Free cash flow
-$113.87M
Reported periodTrailing twelve months